Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 4/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | JAK3 | P52333 | 3/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8041792 | 0.90 | PIK3CB (0.43) | MAPK1PIK3CBAKT1AKT2IGF1R | |
| SCHEMBL8034850 | 0.86 | PIK3CB (0.40) | MAPK1PIK3CBIGF1RJAK2EGFR | |
| SCHEMBL7953230 | 0.85 | PIK3CB (0.44) | MAPK1PIK3CBIGF1RJAK2JAK1 | |
| SCHEMBL3239677 | 0.84 | MAPK1 (0.36) | MAPK1PIK3CBAKT1AKT2EPHB3 | |
| SCHEMBL8037395 | 0.82 | IGF1R (0.38) | MAPK1PIK3CBIGF1RKCNH2JAK2 | |
| SCHEMBL13099810 | 0.82 | PIK3CB (0.41) | MAPK1PIK3CBAKT1AKT2IGF1R | |
| SCHEMBL7950685 | 0.81 | ALDH1A1 (0.43) | MAPK1PIK3CBJAK2JAK1JAK3 | |
| SCHEMBL8049613 | 0.81 | ATM (0.42) | MAPK1PIK3CBIGF1RKCNH2JAK2 | |
| SCHEMBL8043064 | 0.79 | EGFR (0.41) | MAPK1PIK3CBIGF1RKCNH2JAK2 | |
| SCHEMBL8037402 | 0.79 | APOBEC3A (0.46) | MAPK1PIK3CBIGF1RKCNH2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| WO-2010027114-A1 | USE OF PYRAZOLE-PYRIDINE DERIVATIVES AND ITS SALTS FOR TREATING OR REVENTIN OSTEOPOROSIS | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009038385-A2 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | MAP3K20, MAP3K3, MAP3K1 | MAPK1 164/4885PIK3CB 101/4885AKT1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.